In a report issued on January 30, Allison Poliniak from Wells Fargo maintained a Hold rating on Canadian National Railway (CNI – Research Report), with a price target of $130.00. The company’s shares closed last Monday at $121.16.
According to TipRanks.com, Poliniak is a 5-star analyst with an average return of 15.4% and a 63.5% success rate. Poliniak covers the Industrial Goods sector, focusing on stocks such as Westinghouse Air Brake Technologies, Expeditors International, and Knight Transportation.
Canadian National Railway has an analyst consensus of Hold, with a price target consensus of $130.99, representing a 6.8% upside. In a report issued on January 21, Raymond James also maintained a Hold rating on the stock with a C$168.00 price target.
The company has a one-year high of $136.22 and a one-year low of $100.66. Currently, Canadian National Railway has an average volume of 1.22M.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CNI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1919, Canadian National Railway Co. is a Canada-based company which is engaged in rail and related transportation business. Its services include rail, intermodal, trucking, supply chain services, business development, and maps and network. The company offers its services in industries including automotive; coal; fertilizer; food and beverages; forest products; dimensional loads; grain; metals and minerals; and petroleum and chemicals.
Read More on CNI:
- Union Pacific (UNP) Receives a Hold from Wells Fargo
- Abeona Therapeutics (ABEO) Receives a Hold from Leerink Partners
- Leerink Partners Maintains Their Hold Rating on Wave Life Sciences (WVE)
- Leerink Partners Sticks to Its Hold Rating for Bluebird Bio (BLUE)
- Leerink Partners Maintains Their Buy Rating on Decibel Therapeutics (DBTX)